Summary
A 2026 Frontiers in Molecular Neuroscience review explores how psychoplastogens—psychedelic-like compounds—restore neuroplasticity in brains damaged by chronic stress and addiction. These agents rapidly enhance BDNF/TrkB signaling for better emotional regulation and stress resilience, contrasting traditional antidepressants' slow action. Preclinical data supports sustained neural growth, with potential for treating addiction and related mental health issues.
Key Takeaways
- Psychoplastogens rapidly activate BDNF/TrkB/mTOR pathways to promote neural growth, unlike slow traditional antidepressants[2][3].
- Preclinical data shows effects after brief exposure (15 min), sustaining dendrite arborization and synapse formation[3][5].
- No consistent peripheral BDNF rise in humans, but brain plasticity may still occur, especially with baseline deficits[1].
- Potential for addiction recovery via enhanced emotional regulation and fear extinction, with psychedelics like DMT showing promise[4][5].
- Risks include region-specific maladaptive plasticity and abuse liability, tempering therapeutic enthusiasm[2][4].
Balanced Perspective
The review synthesizes evidence that psychoplastogens promote neuroplasticity through BDNF/TrkB signaling, effective in preclinical models for addiction recovery under chronic stress[1][2]. Human peripheral BDNF levels show no consistent elevation post-treatment, though brain changes may not reflect in blood and require time or baseline deficits to manifest[1]. Functional connectivity improvements appear in imaging studies, but clinical translation remains preliminary with mixed findings[1][5].
Optimistic View
Psychoplastogens represent a breakthrough in addiction recovery, inducing rapid dendrite growth and synapse formation via BDNF/TrkB and mTOR pathways after just 15 minutes of exposure, far surpassing chronic antidepressants[3][5]. This could enable quick restoration of emotional regulation circuits, offering hope for lasting remission in substance use disorders and even broader applications like stroke recovery[4]. Patients and clinicians should be excited by preclinical successes with ketamine, LSD, and DMT, paving the way for personalized, fast-acting therapies.
Critical View
Despite preclinical promise, human studies reveal no significant BDNF increase from psychoplastogens, questioning their reliability for brain recovery[1]. Risks include maladaptive plasticity, like amygdala overactivation exacerbating anxiety or mesolimbic changes promoting addiction[2]. Overlooked dangers involve abuse potential, as with ketamine, and unproven long-term effects in addicted populations, potentially delaying proven treatments[4].
Source
Originally reported by frontiersin.org